China Sky One Medical, Inc. Announces Guidance for Second Quarter and Full Year 2008

HARBIN, China, June 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (Amex: CSY) (“China Sky One Medical,” “CSY”), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced financial guidance for the second quarter and

full-year 2008 periods.

China Sky One Medical, Inc. estimated that second quarter gross revenue would climb 57% over the first quarter of 2008 to $19.5 million and that gross margin for the quarter is expected to be approximately 78%. Net income would reach an estimated $6.4 million, or $0.43 per fully diluted share based on 14,888,310 quarterly diluted shares outstanding as of March 31, 2008, and net margin would be approximately 32.8%. The sharp increase is mainly due to the following factors: First, products introduced from Heilongjiang Tianlong Pharmaceutical, Inc., which China Sky One Medical acquired in March, entered the markets rapidly and have had strong sales. Second, China Sky One has launched advertising promotions for its popular external use products, including Slim Patch Body-Beauty Plaster, Hemorrhoid Ointment, Compound Camphor Cream and Blood Pressure Depress Patches, which have stimulated sales. Finally, the second and third quarters are historically seasonally strong sales periods in the pharmaceutical market.

China Sky One also updated guidance for its full-year 2008 gross revenue and provided guidance for net income and earnings per share. The company expects 2008 gross revenue in the range of $81 million to $83 million and gross margin to be approximately 78.5%. Net income for 2008 is estimated to be between $25.9 million and $26.6 million, or $1.74 to $1.79 per fully diluted share based on 14,888,310 quarterly diluted shares outstanding as of March 31, 2008, and net margin is expected to be approximately 32%. Previously, the company had expected gross revenue in 2008 of approximately $80 million and gross margin to be approximately 78.5%.

“We are confident that we will achieve significant revenue growth going forward as we continue to implement our strategy of hiring direct territory managers and sales agents to further strengthen our distribution channels,” said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical, Inc. “In addition, we plan to continue with our research and development efforts and to make strategic acquisitions.”

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company whose principal operations are through its subsidiaries, which are engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic kit products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (‘‘TDR’’) and Harbin First

Bio-Engineering Company Limited ("First"), the Company manufactures and distributes over-the-counter pharmaceutical products as its primary revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Mr. Liao Xiaoqing, CFO

Tel: +86-0451-53994069

Email: cntiandiren@yahoo.com.cn

Investor Relations Contact:

CCG Elite Investor Relations Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Website: http://www.ccgelite.com